Literature DB >> 23980236

Clinicopathological analysis of patients with non-muscle-invasive bladder cancer: prognostic value and clinical reliability of the 2004 WHO classification system.

Naotaka Nishiyama1, Hiroshi Kitamura, Toshihiro Maeda, Satoshi Takahashi, Naoya Masumori, Tadashi Hasegawa, Taiji Tsukamoto.   

Abstract

OBJECTIVE: The aim of this study was to clarify the prognostic value and clinical reliability of the 2004 World Health Organization classification system of non-muscle-invasive bladder cancer.
METHODS: Between January 1995 and November 2010, 153 patients were diagnosed with non-muscle-invasive bladder cancer. We used a substage system that discerns T1-microinvasive (T1m, 42 patients) and T1-extensive-invasive (T1e, 37 patients) cancers.
RESULTS: There were 2 (1.3%), 89 (58.2%) and 62 (40.5%) cases of Grade 1-3 urothelial carcinoma, respectively, on the basis of the 1973 World Health Organization classification system. Of these, 37 (24.2%) and 116 (75.8%) were graded as low and high on the basis of the 2004 World Health Organization classification system. All of the cases with progression (15 patients) were diagnosed as high grade at the time of primary transurethral resection of the bladder tumor. Based on the Kaplan-Meier analysis, the 2004 World Health Organization classification system accurately predicted tumor recurrence (P = 0.029) and progression (P = 0.031). The 5-year recurrence-free survival rates in patients with low-grade and high-grade tumors were 68.7 and 47.1%, and the 5-year progression-free survival rates were 100 and 89.0%, respectively. In the high-grade T1 cases, the substage (T1m or T1e) was a significant predictor of tumor recurrence (P = 0.001) and progression (P = 0.020).
CONCLUSIONS: The 2004 World Health Organization classification system accurately predicts the risk of recurrence in primary non-muscle-invasive bladder cancer cases and has the same accuracy when predicting the risk of progression as the 1973 World Health Organization classification. Furthermore, the substaging system for high-grade T1 tumors is useful in predicting both recurrence and progression.

Entities:  

Keywords:  1973 WHO classification system; 2004 WHO classification system; non-muscle-invasive bladder cancer; substaging system

Mesh:

Year:  2013        PMID: 23980236     DOI: 10.1093/jjco/hyt120

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  5 in total

1.  An insight into the diagnostic and prognostic value of HOX A13's expression in non-muscle invasive bladder cancer.

Authors:  Nouha Setti Boubaker; Aymone Gurtner; Nesrine Trabelsi; Isabella Manni; Ahlem Blel; Ahmed Saadi; Marouene Chakroun; Zeineb Naimi; Selim Zaghbib; Meriam Ksontini; Khedija Meddeb; Soumaya Rammeh; Haroun Ayed; Mohamed Chebil; Giulia Piaggio; Slah Ouerhani
Journal:  J Clin Lab Anal       Date:  2022-07-19       Impact factor: 3.124

2.  Review: Application of Nanoparticles in Urothelial Cancer of the Urinary Bladder.

Authors:  Chieh-Hsiao Chen; Tzu-Min Chan; Yi-Jhen Wu; Jia-Jin Chen
Journal:  J Med Biol Eng       Date:  2015-08-11       Impact factor: 1.553

3.  Expression pattern of p53-binding protein 1 as a new molecular indicator of genomic instability in bladder urothelial carcinoma.

Authors:  Katsuya Matsuda; Tatsuhiko Kawasaki; Yuko Akazawa; Yuhmi Hasegawa; Hisayoshi Kondo; Keiji Suzuki; Masachika Iseki; Masahiro Nakashima
Journal:  Sci Rep       Date:  2018-10-19       Impact factor: 4.379

4.  Assessment of Histopathological Parameters Useful in the Diagnosis of Low Grade Non-Invasive Urothelial Carcinomas.

Authors:  A Ș Săndulescu; A E Stepan; C Mărgăritescu; A E Crișan; C E Simionescu
Journal:  Curr Health Sci J       Date:  2019-12-30

5.  Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis.

Authors:  Mehdi Kardoust Parizi; Dmitry Enikeev; Petr V Glybochko; Veronika Seebacher; Florian Janisch; Harun Fajkovic; Piotr L Chłosta; Shahrokh F Shariat
Journal:  World J Urol       Date:  2019-09-06       Impact factor: 4.226

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.